$ACXP
Acurx Pharmaceuticals, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Staten Island, NY
ACXP chart
What traders are saying about $ACXP
Latest postsAcurx Pharmaceuticals, Inc. news
- Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Yahoo Finance ·
- From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
Yahoo Finance ·
- Acurx Pharmaceuticals, Inc. Estimates – NASDAQ:ACXP
TradingView ·
- Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
Yahoo Finance ·
- Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Yahoo Finance ·
- Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Yahoo Finance ·
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
Yahoo Finance ·
- Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
Yahoo Finance ·
- Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
Yahoo Finance ·
- Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Yahoo Finance ·
- Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
app.moby.co ·
- Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Yahoo Finance ·
Acurx Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M |
| Diluted EPS | $-5.32 | $-17.45 | $-1.15 | $-1.12 |
| Total assets (year end) | $7.7M | $3.9M | $7.7M | $9.4M |
| Cash and equivalents (year end) | – | – | – | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Acurx Pharmaceuticals, Inc.
- Ticker
- ACXP (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Staten Island, NY
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1736243
- Former names
- Acurx Pharmaceuticals, LLC
Frequently asked questions
What exchange is Acurx Pharmaceuticals, Inc. listed on?
Acurx Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol ACXP.
What industry is Acurx Pharmaceuticals, Inc. in?
Acurx Pharmaceuticals, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Acurx Pharmaceuticals, Inc. headquartered?
Acurx Pharmaceuticals, Inc.'s business address on file with the SEC is in Staten Island, NY.
When does Acurx Pharmaceuticals, Inc.'s fiscal year end?
Acurx Pharmaceuticals, Inc.'s fiscal year ends on December 31.